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ABSTRACT
The technologies and processes used in large scale cell bioprocessing, namely 
the impeller based stirred suspension bioreactor, were designed for the growth of robust 
and often immortal cell lines to produce protein based therapeutics. The turbulent fluid 
environment created by such systems was not designed to accommodate the delicate 
nature of stem cell suspension culture -  in particular, to maintain the low shear stress 
and homogeneity required to retain an undamaged cell and unaltered phenotype. While 
new bioreactor designs have been developed to address the unique environmental needs 
of stem cell cultures, industrial volume scale-up is still unavailable.
In this work, a novel biomimetic mixing mechanism utilizing a silicone 
diaphragm and an alternating actuation mechanism has been designed and developed to 
produce adequate fluid mixing while maintaining a low shear stress environment. The 
unique design, characterized on a bench-top scale, has been scaled-up over a range of 
volumes from 100 -  3000 ml. Using particle image velocimetry, the fluid dynamics 
created by the novel mixing mechanism were qualitatively and quantitatively analyzed.
The mixing mechanism produced adequate fluid mixing within the vessel while 
maintaining mean shear stress levels more than 100 times lower than seen in impeller 
based spinner flasks. Furthermore, the mixing profile and mean shear stress levels
remained well below requirement levels (< 0.3 regardless of reactor volume. In
conclusion, we have developed a novel mixing system which overcomes shear stress 
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Bioprocess Industry Background 
In the late 20th century the biopharmaceutical industry transformed modern 
medicine with the large scale manufacture and use of protein therapeutics produced by 
engineered mammalian cells to treat a wide range of diseases [1]. Today, nearly 70% of 
all recombinant protein therapeutics are produced through robust Chinese hamster ovary 
(CHO) cells, with annual sales exceeding $30 billion worldwide for CHO cell-derived 
products alone [2]. CHO cells are the preferred production vehicle for a number of key 
reasons: robustness, ease of use, production track record, and most importantly, their 
suspension scalability to volumes in excess of 20000 liters in industrial bioreactors [3].
CHO cells are routinely cultured in bioreactors, which are devices in which 
biological or biochemical processes occur under closely monitored and tightly 
controlled conditions including homogeneity, mass transfer, pH, temperature, and 
oxygen concentration [4].
Two common bioreactor platforms currently exist: static and suspension 
reactors. Static bioreactor systems (t-flasks) are open systems where the culture 
chamber and its surroundings must be opened during inoculation, medium exchange, 
and harvesting. These processes increase contamination potential [5]. Furthermore, due
to the planar nature of static systems, mixing and concentration gradient limitations 
arise. Conversely, suspension bioreactors used in the production of molecular 
therapeutics are operated under well mixed closed conditions, which ensure a high 
quality, reproducible product.
The stirred tank bioreactor is the predominate bioreactor from bench-scale 
through large scale production due to its simplicity, performance, and industry 
experience [6], [7]. While stirred vessels are the industrial gold standard, there are other 
suspension culture systems such as cell culture bags, hollow fiber cartridges, fluidized 
or packed-beds, bubble-column or air-lift vessels, rotary cell culture systems, and 
microfluidic devices; each with their specific advantages and disadvantages [8].
Cells are typically grown on 100 -  300 p,m microcarriers in large scale 
suspension bioreactors in order to maximize surface to volume area [9], [10]. In such 
cases, the bioreactor mixing mechanism must utilize very low agitation intensities 
because the microcarrier is on the same order of magnitude as the eddy sizes in highly 
turbulent flow environments [11] and therefore more susceptible to hydrodynamic 
damage than single cells in suspension.
Bioreactor Mixing Functionality 
Mixing is a critical component of any stirred tank bioreactor. Insufficient mixing 
leads to settling and inhomogeneous environmental zones due to limited mass transfer. 
Inadequately mixed commercial culture systems with significant dissolved CO2 
concentration gradients lead to drastic pH differences between fluid parcels within the 
chamber [6], [10], [12]. Inadequate mixing using impellers also results in dissolved O2
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gradients, which have a great effect on the cellular metabolism and final product’s 
quality [11], [13]. A case-by-case solution to this challenge has typically been 
developed as the bioreactor volume process is scaled up, resulting in numerous impeller 
configurations [6].
All impellers are designed to homogenously mix cells, gases, and nutrients 
throughout the bioreactor vessel. This action evenly disperses oxygen and nutrients 
required for healthy growth, discourages settling, and maintains a uniform culture 
temperature [14]. In stirred bioreactors, this agitation causes energy transfer from the 
impeller to the culture medium, resulting in areas of intense turbulence and localized 
shear stresses on particles in the reactor. This occurs regardless of suspension 
methodology: single cells in suspension, cells attached to microcarriers, or the surface 
of cell aggregates [15]. The sensitivity of mammalian cells to shear forces (from shear 
induced cellular response [11] to lysis) has led to an extensive effort to vary and 
optimize the impeller mixing system to find the balance between sufficient mass 
transfer and hydrodynamic damage induced by the sweeping impeller blades.
Environmental Effects on CHO Cells 
The major processing stress common to all mammalian cell culture is 
hydrodynamic shear stress, whether in stirred tank reactors or during manual cell 
culture operations. Three mechanisms of potential damage to cells have been reported: 
collisions between cells or microcarriers with other beads, collisions with parts of the 
reactor (impeller and probes), and interactions with turbulent eddies the size of the cell 
or microcarrier [16]. Fluid associated shear stress can result in cell death, cell apoptosis,
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and nonlethal physiological responses [11]. Nonlethal responses can be found in the
d.'V'n.csrange of 1 -  10 Pa (10-100 ) and can alter cell function, affect proliferation and
viability, alter metabolism, and affect the surface content of cellular receptors of CHO 
cells [11]. Optimized impeller designs have led to stirred bioreactors within the safe 
shear stress tolerance range for robust mammalian cells [14].
Stem Cell Therapy
As protein therapy did 20 years ago, stem cells are poised to revolutionize 
modern medicine due to their regenerative potential and multilineage differentiation 
capacity. Stem cell therapies may well form the basis of future healthcare with 
applications in regenerative medicine, tissue engineering, and drug screening. 
Prochymal®, developed by Osiris Therapeutics, is a mesenchymal stem cell (MSC) 
therapeutic used to treat acute graft-versus-host disease in children which gained 
Canadian health regulators’ approval in early 2012 making it the first stem cell drug to 
be approved for a systemic disease anywhere in the world [17]. Industrial and academic 
innovators are concurrently investigating the use of stem cells for the treatment of 
multiple diseases including neurodegenerative disorders [18], cardiac disease [19], 
diabetes [20], spinal cord injury [21], and amyotrophic lateral sclerosis [22].
Successful implementation of stem cell therapies will require a system capable 
of producing both the quality and quantity of cells required for widespread therapeutic 
benefit at an affordable cost. The number of cells utilized in cell therapy applications 
falls in the range of tens of millions to billions of cells per patient, per treatment [23].
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For example, following myocardial infarction approximately 1x109- 2x109 cells are 
required to replace damaged cardiac tissue [19], [24]. For the treatment of diabetes, 
successful islet transplantation requires approximately 9000 islets per kilogram body 
weight [25] or 1.3x109 insulin producing P-cells per 70-kg patient [20]. A bioartificial 
liver device comprising of only 10-20% of the number of native cells contains 
approximately 1010 hepatocytes and can support a patient with severe hepatic failure 
[26]. These examples suggest that 1 -  2 billion cells per patient is a useful benchmark to 
estimate production requirements in industrial stem cell bioprocess development, which 
would require 1-3 liters of suspended cell culture [27]. In addition, it is important to 
highlight that while molecular therapeutics are harvested as cell products, the stem cell 
itself is the product for stem cell therapies.
Cell Sources
Mesenchymal stem cells (MSC) are an attractive adult stem cell source because 
of their ease of access, isolation, and extensive expansion capability [28], [29]. 
Additionally, MSCs can be preserved and stored with minimal loss in potency [30]. 
These stem cells are also capable of multilineage differentiation [31], can exert an 
immunosuppressive effect in vitro and in vivo by acting on all immune effectors [32], 
and exhibit trophic effects mediated by the wide range of growth factors and cytokines 
they produce [33]. Finally, owning to their lack of a major histocompatibility complex, 
human trials of MSCs have shown no adverse reactions to allogeneic versus autologous 
transplants, which makes these cells ideal candidates for large scale expansion for stem
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cell therapies [34], [35]. MSCs have shown great capacity for clinical applications in 
cardiovascular [36], neurological [37], and musculoskeletal disorders [38].
While MSCs have shown great potential for use in clinical settings, they are 
found in very low numbers in human tissue. The frequency in human bone marrow has 
been estimated to be on the order of 0.001 -  0.01% of total nucleated cells. In addition, 
the frequency declines with age, from 1 per 104 in a newborn to approximately per 
106 nucleated marrow cells in an 80 year old individual [39]. Therefore, large scale in 
vitro expansion, 30+ fold, is required in order to reach the quantity of cells required for 
clinical application.
Environmental Sensitivity of MSCs 
Stem cells respond to various environmental cues in vitro in order to proliferate, 
maintain potency, or regulate differentiation. These cues can include biochemical 
factors, cell-cell interactions, cell-matrix interactions, and mechanical stimuli [40], [41], 
[42]. Dissolved O2 concentration plays an important role in the regulation of MSC 
proliferation and differentiation [43][44]. Culture pH also has a considerable effect on 
the metabolic activity of cells and is carefully regulated in vivo by complex mechanisms 
influenced by carbon dioxide, lactate production and many elements of serum. Growth 
and differentiation of stem cells is also strongly dependent on pH [45]. The effects of 
hydrodynamic fluid shear stresses and strains have also been linked to the induction of 
physical, biochemical, and epigenetic cellular responses, all of which directly affect 
MSCs ability to proliferate, maintain potency, or differentiate [40], [42].
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There is growing evidence that MSC proliferation and differentiation, such as 
osteogenic differentiation, are both sensitive to hydrodynamic fluid shear stress [46]. In 
three-dimensional MSC seeded constructs, an average surface shear stress of 5x10"5 Pa
dvnes(0.0005 cm2 ) corresponded to increased proliferation and cell viability, whereas higher
3 dynesshear stresses of 1x10 Pa (0.01 ~—r )  resulted in the upregulation of mRNA 
expression of a variety of osteoblastic proteins leading to expression of alkaline 
phosphatase activity and increased calcium deposition [47]. Thus, in vitro, these 
microenvironmental conditions must be carefully replicated, monitored and maintained.
MSC Expansion
While the molecular therapy industry has optimized the large scale manufacture 
of recombinant proteins using mammalian cells in large-scale bioreactor vessels, the 
field of stem cell therapy is still in its infant stages. Traditionally, culturing stem cells 
has been performed on flat, two-dimensional surfaces such as tissue culture flasks and 
well-plates to produce pure populations of undifferentiated cells. This is due to the t- 
flask’s simplicity, low cost, and ease of handling. Based on the benchmark quantity 
requirements of 1 -  2 billion cells per patient defined above, multiple two-dimensional 
parallel plates are recently being used as a means of large scale cell manufacture for 
clinical applications. Current multiple parallel plates can provide the cell numbers 
required for clinical trial testing and limited commercialization. A 40 layer vessel has a 
large surface area available for growth which can be manipulated by several robotic 
systems and drive the lot size to 30 -  100 billion cells / lot [48].
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Although they are easy to use, static cultures such as 2D t-flasks have industrial 
scale limitations including concentration gradient development, lack of online control of 
environmental conditions, and limited surface areas to volume ratios [24]. Stirred 
bioreactors, which are successfully used in the molecular therapeutics industry due to 
their large scale production capabilities, are now being examined for the expansion of 
stem cells. These stirred bioreactors provide high surface area to volume ratios and a 
more tightly controlled environment for growth, which may be critical for successful 
MSC cultivation as seen by their sensitivity to environmental conditions [42], [49]. 
Several groups have reported success in expanding MSCs on microcarriers and in 
suspension in stirred vessels while retaining differentiation potential [50], [51], [52].
In order to circumvent the high shear environment imparted by impeller based 
stirred suspension cultures, NASA develop a rotating-wall vessel (RWV) optimized to 
produce laminar flow and minimize the mechanical shear and turbulence on cell 
aggregates in culture [53]. The RWV is composed of a horizontally rotating cylindrical 
culture vessel with a coaxial tubular oxygenator. This bioreactor is thought to largely 
solve the challenges of suspension culture -  suspending cells and microcarriers without 
inducing large degrees of shear and turbulence while providing adequate nutrition and 
oxygenation [54]. Although RWV provides efficient gas transfer and low shear 
environment for cell growth, they are limited in scalability to a working volume of 500 
ml and therefore may not be suitable for large scale expansion of allogeneic therapies 
[55].
Thus, as evident from the history and current industry standards, the bioprocess 
techniques and methodologies widely used in protein therapy have been applied to the
8
9infant industry of stem cell therapy. However, it is important to again highlight that 
while molecular therapeutics are harvested as cell products, the stem cell itself is the 
product for stem cell therapies. The industry standard stirred bioreactor vessel was not 
designed to address the delicate and unique requirements of stem cells. Existing designs 
which fulfill these requirements, such as the RWV, face serious scalability challenges 
which may invalidate them as industrial volume candidates. Table 1.1 shows the 
advantages and disadvantages of select bioreactor systems. A novel bioreactor mixing 
mechanism with low shear is needed to deliver both the quality and quantity of cells 
required by the regenerative medicine and tissue engineering applications of the near 
future.
Design and Development 
The initial design goal of this research project was to create a proof of concept 
mixing system which challenges and seeks to shift current gold standard means of 
suspension culture through the use of a novel mixing diaphragm based upon proven 
legacy technology and designed using a requirements based approach that will result in 
mixing process with subthreshold shear.
Legacy Technology
Refine Technology’s patented Alternating Tangential Flow (ATF™ System) has 
revolutionized the biopharmaceutical industry and recently took second place in the 
“Technology of the Decade” awards presented by Bioprocess International [56]. The 
ATF™ System is based upon the technology of alternating tangential flow, created by
the action of a diaphragm moving upwards and downwards within a pump head, 
connected to filter housing and attached to a standard bioreactor, Figure 1.1. 
Applications of this system include: concentrated fed-batch, high productivity 
continuous culture, virus production and filtration, rapid media removal and exchange, 
clarification and harvest, cell and product concentration, microcarrier wash, perfusion, 
diafiltration, medium exchange and cell separation. The interest in the system as the 
legacy technology is due to the linear scalability from benchtop to manufacturing that is 
possible with such a simple technology. The large surface area of the diaphragm 
minimizes shear and supports extremely high cell concentrations. It is hypothesized that 
a novel mixing mechanism based upon ATF™ technology would overcome limitations 
with stirred suspension bioreactors associated with ex vivo expansion of MSCs.
Design Requirements 
The bioreactor design requirements will need to address the metabolic and 
environmental needs of the MSC cells including availability of nutrients and removal of 
waste products, appropriate cell attachment conditions, hydrodynamic conditions, and a 
clear harvesting and storage protocol. The first leg in achieving the next generation of 
bioreactors tailored for MSC expansion is the focus of this thesis. The work presented 
here was to identify an appropriate design which featured a mixing mechanism that
would produce homogenizing low shear stresses (< 0.3 “ p “) through radial mixing
without negatively impacting media mixing and distribution. This is in stark contrast to 
the rotational or radial mixing of standard impeller approaches used in current
10
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bioreactors where shear stresses are orders of magnitude higher (gold standard 
approach). Development of the low shear stress mixing mechanism would be the first 
step in achieving the design requirements needed to allow Refine Technology to 
challenge the current clinical practice of stem cell expansion and thereby set the stage 
for industrial scale regenerative medicine and tissue engineering applications.
Biomimetic Innovation
John O. Dabiri et al. at the Biological Propulsion Laboratory of California 
Institute of Technology have extensively studied the dynamic locomotion mechanisms 
of aquatic organisms, namely jellyfish [57]. Their studies encompass the transport of 
fluid mass, momentum and general fluid dynamics generated through the swimming 
motions of jellyfish [58]. Of particular interest is the concept of optimal vortex 
formation during jellyfish motion. Multiple studies have evaluated the influence of the 
vortex ring formation and vortical mixing on the environmental fluid [59], [60]. The 
locomotive motion of jellyfish has been found to be highly efficient and even a 
significant contributor to ocean mixing [61].
In this work, it is hypothesized that incorporating the general geometric relations 
of jellyfish in a diaphragmatic mixing mechanism will produce sufficient mixing in an 
efficient, low shear manner. These geometric considerations include the bell shape and 
aspect ratio, membrane thickness, and the length and spacing of the fins. These 
characteristics will be included in the geometric design of the diaphragm. Furthermore, 
notable functional design elements for the biomimetic device derived from the jellyfish 
swimming analysis are (1) alternating up and down motions, (2) motionless delays at
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the end of both the upstroke and downstroke, (3) radial symmetry, and (4) flexible 
hinges/fins that are free to undergo flapping deformations due to the cyclic motion 
within the fluid [62].
Scalability
A review of the bioreactor technologies reveals the need for a design which 
uniquely fulfills fluid dynamic requirements including homogenous mixing and low 
shear stress [55]. However, of equal importance is the capacity for scalability [7]. 
Current challenges in developing a system capable of clinical production volumes 
include: (1) limited ability to scale-up or down, and (2) mixing profiles that are 
predictable, controllable, and reproducible throughout scale-up to production volumes 
[55], [5], [63]. For a design solution to gain traction as a viable alternative to stirred 
vessel systems, it must be scalable to production volumes comparable to those of stirred 
reactors [6].
The requirements based design approach identified requirements from four main 
areas: (1) stem cell needs, (2) legacy technology, (3) jellyfish biomimicry, and (4) 
clinical/industrial need for scalability. A summary of these requirements is provided in 
Table 1.2.
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Table 1.1 Comparison of Select Existing Bioreactors
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Table 1.2 Design Input Requirements
Source Requirement
Stem Cell Need Reduced turbulent hydrodynamic environment through 
minimized or eliminated small eddy formation.
Large rotational flows which predictably and adequately 
distribute fluid movement
Homogenous low shear stresses (< 0.3 ~ j f “)
Legacy
Technology
Alternating up and down motions 
Direct contact with culture media
Jellyfish
Biomimicry
Alternating up and down motions
Motionless delays at the end of the upstroke and downstroke 
Radial symmetry
Flexible hinges/fins that are free to undergo flapping 





Figure 1.1 The Alternating Tangential Flow (ATF™) system is used as a perfusion 
accessory for existing bioreactors. The system utilizes a spherically housed silicone 
diaphragm, which is pneumatically actuated in alternating up and downstrokes. This 




A final design was selected to meet the requirements derived from the legacy 
ATF™ technology, biomimetic model, proof of concept prototypes, and the delicate 
nature of MSCs as design input as seen in Figure 2.1. The proposed system consists of 
an inverted jellyfish-like diaphragm that is mechanically actuated up and down. The 
diaphragm is fixed in the bottom of the reactor vessel and is in direct contact with the 
culture media.
Mixing Mechanism Operation 
A silicone diaphragm is affixed to the bottom surface of a curved bioreactor
vessel. The deformation of the diaphragm results in a displacement of the culture media
in alternating directions, thus promoting fluid mixing within the reactor chamber.
Furthermore, the diaphragm design incorporates biomimetic elements such as radial
symmetry and flexible hinges/fins. These elements result in the formation of both
starting and stopping vortex rings, which has been shown to greatly influence localized
fluid dynamics. The silicone diaphragm has an interfacing sleeve which elastically fits
over a linear actuator (Model 43H4A-2.33-815, Haydon Kerk Motion Solutions, Hollis,
17
USA) coupler aligned concentrically with the diaphragm and vessel; see the system 
schematic in Figure 2.1. Precise control of stroke length, stroke speed, and delay 
between upstrokes and downstrokes is implemented using a custom control program 
that was designed using LabView (USB-6211 National Instruments, Austin, USA) and 
a microstep driver (Gecko, Energy Micro, Oslo, Norway).
Prototype Fabrication 
The selected design was modeled using SolidWorks 3D software (SolidWorks
Corporation, Waltham, USA). The 3D models were converted to g-code computer-
aided manufacturing files using both CamBam and MecSoft Corporation’s Visual Mill
software. The curved reactor bottom geometry was machined using CNC milling from
stock cast acrylic and then polished to clear surfaces, see Figure 2.2. The machined
acrylic reactor base was then fused to a 2.5 inch (63.5mm) clear cast acrylic tube using
methylene chloride. Additionally, molds for the silicone diaphragm were printed using
an Alaris 30 (Objet, Eden Prairie, USA) rapid prototyping printer. The silicone
diaphragm was cast in the custom molds using a 1:10 ratio of VST50 (Factor II Inc.,
Lakeside, USA) silicone to catalyst. A mounting base to house the linear actuator was
precision milled from polyurethane foam board. Each upstroke and downstroke of the
mixing diaphragm had a stroke rate of 13.49 mm/sec with a stroke length of 17.4625
mm. The cycle is delayed with a 3 second pause following both the upstroke and




Particle image velocimetry (PIV) is used to visualize particle motion within a 
fluid flow. It is used as a quantitative tool that can verify that the proposed system 
achieves the design goals of mixing with concomitant low shear. As demonstrated by 
Sucosky et al. particle-imaging velocimetry utilizes optical techniques and statistical 
analyses to determine the instantaneous velocity fields within a fluid on a given 
reference plane [64]. This technique has been extensively characterized and optimized 
by groups such as Adrian, 1991 [65]; Willert and Gharib, 199l [66]; and Wetserweel, 
1997 [67].
In this work, we used PIV analysis to determine the velocity magnitudes, shear 
stresses, vortex locations, and streamlines within the mixing fluid. The basic schematic 
for the PIV analysis employed is seen in Figure 2.3. The flow is tracked by optically 
reflective/fluorescent particles that are suspended within the fluid. A planar laser is 
projected through the medium and creates a reference plane of reflective particles. A 
Vision Research high speed camera (Phantom MIRO eX4) tracks the position of these 
particles at a rate of 50 frames per second. A given particle is “tracked” between 
adjacent frames by comparing the position of a given particle at two adjacent frames. 
Then using the frame right and displacement distance, a calculation can determine the 
instantaneous velocity of that particle. Correlation for all points in a frame results in a 
velocity gradient tensor which describes the change of velocity throughout the flow, as 
seen in Equation 2.1. Further computational analyses of these velocity fields yield 
multiple fluid dynamic parameters, such as dilation and shear stresses (Equation 2.2) 
and vorticity or rotation (Equation 2.3), of any fluid parcel at a given point.
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In Equation 2.1, represents the index notation velocity component du in a
given axial direction (i, j, k) with relation to each standard orthogonal axis (i, j, k). The 
resultant is a 3x3 matrix of the three-dimensional velocity (m/s) for every fluid parcel in 
the evaluated space. This velocity gradient tensor can be further defined as the 
combination of both the deviatoric element ej (Equation 2.2) and the rotational element
Tij (Equation 2.3). The symmetric term of the velocity gradient,ddu1, is the strain rate
tensor, eij. The diagonal of the strain rate tensor encodes the compression or expansion 
of a fluid element, while the off-diagonal elements represent the shear rate of the fluid 
element. The antisymmetric component of the velocity gradient tensor represents the 
rigid rotation of the fluid element with angular velocity ro.
Prototype Bioreactor Particle Image Velocimetry 
Figure 2.4 shows a custom stabilization and alignment fixture that was 
constructed to ensure repeatable planar illumination and recording across multiple trials. 
The fixture included an adjustable mounting bracket for the green laser module (Beam 
of Light Technologies, Clackamas, USA) as well as an adjustable mounting base for the
20
high speed camera. The Vision Research high speed camera was placed on the 
mounting base and focused on the center plane of the reactor vessel. The prototype 
bioreactor was filled with 150 mL of distilled water seeded with 212-250 p,m 
fluorescent beads (Cospheric, Santa Barbara, USA) at a density of 2.5 mg/ml wet with a 
surfactant, TWEEN 80 (Sigma Aldrich, St. Louis, USA), prior to use. The system was 
run for a short time until a steady state flow was visually confirmed in the vessel. The 
flow was then captured at a rate of 50 frames per second for roughly 25 seconds of 
continuous cyclic actuation of the biomimetic ATF diaphragm mixing mechanism. The 
captured video was processed using an open-source image processing package (FIJI) 
into an image stack with sequential image slices representing a 20 ms time delay [68].
Barrel Distortion Correction 
Successful and credible results from particle image velocimetry rely on the 
accurate location of any given particle within the analysis field. The captured light 
reflected from the fluorescent beads must pass through three mediums: distilled water, 
acrylic, and air. Refraction occurs as the light passes from one medium to another at the 
interface plane according to Snell’s Law (Equation 2.4).
Each 9 is the angle of entry in relation to the normal of the interface plane and 
each n is the refractive index of each material that the light passes through. As the light
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passes through the curved surfaces of a cylinder, barrel distortion, or magnification of 
the fluid within the cylinder, is seen.
A calibration fixture was designed and constructed which consists of a 
calibration plate, aligned brackets, and a removable acrylic cylinder of the same 
dimensions as the prototype bioreactor vessel as seen in Figure 2.5A. The calibration 
plate was dimensioned at 63.5 mm wide to tightly fit inside of the acrylic cylinder. The 
plate was coated with an opaque black aerosol paint and a 0.3 mm hole pattern was 
precisely cut at 3.175 mm vertical and horizontal spacing as seen in Figure 2.5B.
To correct for the refraction that occurs in the captured images, an elastic 
transformation algorithm (BUnwarpJ) was applied to return the images to their true 
locations within the vessel [69]. A schematic of this process flow is shown in Figure 
2.6. First, the calibration fixture was immobilized in relation to the camera using the 
alignment fixture. The camera was focused on the calibration plate plane, which was 
directly aligned with the central plane of bioreactor vessel when mounted. A light 
source was placed behind the calibration plate to illuminate the hole pattern and 
improve image contrast. An image of the calibration plate in open air was recorded. 
Next, the removable cylinder was placed over the calibration plate and the inner space 
was filled with distilled water, causing barrel distortion due to the refraction through the 
water and acrylic cylinder. This distorted image was recorded and the resulting data 
files were loaded into FIJI and the plug-in BUnwarpJ with the water distorted image as 
the ‘source’ and the unaltered air image as the ‘target’.
BUnwarpJ allows correlates landmarks between two images and computes the 
transformation required to match the source image to the target image. The illuminated
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holes in the calibration plate were matched as the correlated landmarks on each image. 
The image registration settings of BUnwarpJ were input per the values in Table 2.2. The 
registration was run and an elastic transform file was obtained. This tranform file was 
then applied to every image slice from the captured actuation video using a custom 
scripted macro through the FIJI plug-in interface.
Correction Validation Method 
To validate the correct transformation a second calibration plate was constructed 
with letter sequences replacing the hole patterns. The same process depicted in Figure 
2.6 was followed with hole pattern transformation field being applied to the distorted 
letter sequence image. This transformation outputted a corrected letter sequence image. 
This corrected image was then quantitatively compared to an open air image of the 
letter sequence to determine the accuracy of the horizontal correction. The corrected 
image can be qualitatively compared to both the raw distorted image and the open air 
image in Figure 2.8. The quantitative comparison can be seen in Figure 2.9. There was 
a difference in the horizontal measurement of 2.6 ± 0.71 mm, or a 97.7% ± 0.63% 
match of the corrected image to the open air image. It was observed that a small region 
directly adjacent to the inner vessel wall on either side of the image was blurred by the 
transformation.
Data Analysis
After correction for barrel distortion, the image stack was loaded into MATLAB 
(Mathworks) using PIVlab, an open source “Time-Resolved Digital Particle Image
23
Velocimetry Tool for MATLAB” [70]. A region of interest containing the flow was 
selected. All default image preprocessing was deactivated. The PIV algorithm was set to 
conduct three interrogation passes for particle correlation. Pass 1 area was set at 100 px 
with an overlap step of 50%, Pass 2 area at 90 px with 50% step, and Pass 3 area at 80 
px and 50% step. Once the correlation between temporally adjacent images was 
complete, the software was spatially calibrated. The open air calibration plate image 
was loaded into PIVlab and the real distance of 3.175 mm was assigned to adjacent 
holes in the image. The time step between image slices of 20 ms was also entered. This 
calibration resulted in equivalent software values of 1 px = 0.11mm and 1px/frame = 
5.48 mm/s.
A single actuation cycle consists of (1) a downstroke, (2) a 3 second delay, (3) 
an upstroke, and (4) a 3 second delay preceding the downstroke of the next cycle. Three 
distinct actuation cycles were independently analyzed. From the calibrated image stack, 
PIVlab derived the following steady-state mean values: streamlines, velocity 
magnitude, vorticity, vortex location, and shear rate. The maximum and minimum 
values of each parameter for the steady-state mean were also recorded. Shear stress is
s^ sdefined as the dynamic viscosity (0.01002 ^  for water at 20°C) multiplied with the 
1
shear rate ( -  ). Statistical analysis consisting of calculating the mean and standard 
deviation of distinct actuation cycles was utilized wherever applicable.
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Mixing System Scale-Up 
To understand the scalability of the novel biomimetic ATF™ mixing 
mechanism, three vessel sizes were fabricated to represent industrial relevant volumes: 
125 ml, 500 ml, and 1000 ml, shown in Figure 2.9. For ease of nomenclature, the three 
vessels were referred to as 125V, 500V, and 1000V. The dimensions of each reactor 
size are listed in Table 2.3. The 125 V and 500V reactor sizes utilized the original 
biomimetic silicone diaphragm. The 1000V reactor used a scaled up silicone diaphragm 
that was 1.5 times bigger in select dimensions while all other parameters are held 
constant, see Figure 2.10. This scaling factor is the same as the increase of the inner 
diameter between the 500V and 1000V sizes. Finally, actuation parameters such as 
stroke rate and delay remained unchanged while stroke length was increased to account 
for the larger diaphragm (Table 2.3).
To better characterize the performance and scalability of the novel mixing 
mechanism, each reactor size (125V, 500V, 1000V) was evaluated at different working 
volumes ranging from 100 -  3000 ml. Refer to Table 2.4 for the list of volumes for each 
respective reactor size. Three distinct actuation cycles were analyzed for each volume.
Low shear homogenous mixing was evaluated by a comparison of the derived 
streamlines, velocity magnitudes, vortex location, and shear rates. The maximum and 
minimum values of each parameter for the steady-state mean of each working volume 
were recorded and analyzed.
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Table 2.1 Prototype Bioreactor Parameters
Parameter Material/Value
Biomimetic ATF diaphragm Silicone, Shore A 30
Motor housing 
Reactor vessel material 









Table 2.2 BUnwarpJ Registration Settings
Parameter Setting
Initial Deformation Fine







Table 2.3 Scaled Reactor Parameters
Reactor Inner Diameter Height Stroke Length Stroke Rate
Size in. cm in. cm in. mm in./s mm/s
125V 2.50 6.35 5.7 14.48 0.6875 17.463 0.5313 13.49
500V 3.75 9.52 8.0 20.32 0.6875 17.463 0.5313 13.49
















Table 2.4 Tested Reactor Volumes











Figure 2.1 The novel biomimetic mixing bioreactor system consists of four key 
elements: (1) the culture vessel which contains the fluid medium, (2) the jellyfish 
biomimetic silicone diaphragm which is mechanically coupled to the (3) linear actuator 
fixed inside the (4) actuator housing.
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Figure 2.2 Curved reactor vessel bottom showing (A) cross-section dimensions (mm) 
and (B) perspective views.
I
Figure 2.3 The basic schematic for particle image velocimetry (PIV). PIV analysis 
utilizes correlation software and a high speed camera to visualize the fluid flow by 
tracking fluorescent particles suspended within the fluid. The suspended particles are 
illuminated with a planar laser.
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Figure 2.4 The custom stabilization and alignment fixture holds the high speed camera 
(upper left corner) directly in line with the center of the prototype bioreactor (lower 
right corner). An acrylic framework ensures that the planar laser (upper right corner) is 
aligned with the center plane of the reactor vessel.
Figure 2.5 Schematic of the particle image velocimetry (PIV) calibration system 
comprising (A) an acrylic base and framework with a removable cylinder, and (B) an 
opaque calibration plate with backlit 0.3 mm holes spaced 3.175 mm in the horizontal 
and vertical directions. Scale bar = 50 mm.
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Figure 2.6 The refraction correction process uses BUnwarpJ to create and elastic 
transformation field from ‘source’ and ‘target’ images. This transform is then applied to 
the raw video slices to relocate the fluoresced particle to their true locations.
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Figure 2.7 The effect of the barrel distortion is seen when the raw images are compared 
to the corrected images. (A) The letter sequence in air without any refraction is aligned 
with the corrected image (B) directly below. In contrast, the same letter sequence in air 
(C) cannot be aligned with (D) the letter sequence image distorted by the water and 
acrylic.
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Figure 2.8 The quantitative comparison of the calibration. (A) The maximum image 
distance between the “E” and “W” letters is measured for all seven visible rows on the 
undistorted image. (B) The maximum image distance between the “E” and “W” letters 
is measured for all seven visible rows on the corrected image.
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Figure 2.9 Three reactor sizes were fabricated to examine the scalability of the novel 
mixing design. From left to right, the sizes were 125V, 500V, and 1000V with 
dimension as seen in Table 2.3
Figure 2.10 Relative size of the 1.5 times scaled silicone diaphragm (right) as 
compared to the original size (left). The original diaphragm was used to actuate the 




Novel Biomimetic Mechanism Flow Characteristics 
Quantified Using PIV 
A novel silicone diaphragm incorporating biomimetic elements was successfully 
designed and fabricated. This diaphragm was attached to a custom bioreactor with a 
linear actuator and was verified to withstand the specified deformation from the 
upstroke and downstroke. The reactor was filled with water and achieved continuous 
actuation without noticeable leaks. The leak test fluid was replaced with 150 ml of 
distilled water with suspended fluorescent beads for flow visualization. The system was 
initiated and allowed to run for 10-15 minutes to ensure that fluid movement within the 
vessel was solely caused by the action of the novel mixing mechanism design. A global 
steady state was visually confirmed before recording the high speed video.
The image transformation process was successfully applied to the prepared 
image stack and was then input into PIVlab. The PIV algorithm was successfully 
completed and the mean flow of each actuation cycle was computed. The mean velocity 
magnitude, Figure 3.1, reveals a centralized column of upward flow through the vessel.
The flow reaches the upper boundary layer of the fluid volume and diverges 
radially toward the edges where momentum and gravity combine to slowly recycle the 
fluid mass down to the vessel bottom to supply the upward column. The mean 
horizontal component of the velocity was 0.08 mm/s ± 0.44 mm/s, suggesting that the 
horizontal flow occurring at the top and bottom of the vessel are balanced radially and 
produce a consistent, uniform centralized flow. The mean vertical component of the 
velocity, Figure 3.2, was 0.37 mm/s ± 1 mm/s with a maximum upward speed of 2.06 
mm/s localized in the central flow column and the maximum downward speed of -0.93 
mm/s found near the radial edge.
This flow pattern of a rising central flow which diverges and returns radially 
down the vessel edges is further exhibited in the streamlines of the mean flow, which 
show the direction any giving fluid element will travel at any point throughout the 
vessel space, Figure 3.3. The visualized cross section is located on the central plane of 
the cylindrical vessel; therefore a 360° rotation of the cross section about its midline is 
representative of the three-dimensional flow. By looking at the vorticity (Equation 2.3) 
and its gradient, the locations of the general vortices in the flow are visible, as seen in 
Figure 3.4. Once again, we see a vortex ring which has an upward moving inner column 
with a radially diverging return flow.
Finally, per Equation 2.1, the mean shear stress caused by the hydrodynamic 
environment can be visualized throughout the flow, see Figure 3.5. The maximum shear 
stress seen in the mean flow was 0.00161 dynes/cm . The higher magnitude stresses 
were localized at the interface region where the central columnar flow interacts with the 
slower moving fluid as you move radially outward from the upward flow to the
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descending flow, reference Figure 3.1. The maximum and minimum stresses are similar 
in magnitude, suggesting symmetrical and predictable flow.
Scaled Vessels Maintain Flow Characteristics
The same calibration, steady state achievement, and video capture were 
successfully completed for all volume intervals for each of the three vessels sizes 
(125V, 500V, 1000V). Qualitative observation of the steady state found that the flow 
profile remained constant at all volumes and scales such that a centralized columnar 
upward flow was seen from the actuating diaphragm to the upper boundary layer of the 
fluid/air interface. Once the upward flow reached the top of the fluid it diverged radially 
and recirculated to the bottom along the radial edge of the vessel.
The mean velocity magnitudes and maximums are displayed in Table 3.1 and 
are graphically compared to the values seen in the 150 ml vessel in Figure 3.6. The 
mean and maximum velocity values for each steady state volume mean are plotted in 
Figure 3.7 as a function of volume and vessel size. All the mean velocity magnitude 
profiles are seen for the 125V, 500V, and 1000V in Figures 3.8-3.11.
The similarity of flow across all volumes and sizes is evident through qualitative 
comparison of the streamlines, Figures 3.12-3.14. Furthermore, the streamlines show 
that all regions within the vessel are included in the flow profile and experience mixing 
motions.
A look at the instantaneous streamline profile of the flow for any given volume 
or size reveals a unique element of multiple counter-rotational vortices. This 
phenomenon is evident in a sample frame from the 900 ml volume in the 500V vessel,
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Figure 3.15. Multiple vortices are visible at various heights along both sides of the 
centralized columnar flow. Additionally, two of the adjacent vortices are counter- 
rotational which is characteristic o f starting and stopping vortices. These vortices are 
present in the swimming wake of jellyfish and functionally aid mixing by sucking 
adjacent fluid into the centralized column. This increases the efficiency of each 
actuation stroke.
Finally, examination of the shear stress profiles for all volumes and sizes, 
Figures 3.16-3.18, reveals that the shear profile and magnitude match those seen in the 
original 150 ml size design. As the design is scaled to larger sizes, Figure 3.19 shows 




Table 3.1 Scale-Up Velocity Magnitudes
Mean Max
Size (m/s) (m/s)
125V 0.00051 ± 0.00023 0.00283
500V 0.00065 ± 0.00021 0.00343
1000V 0.00069 ± 0.00021 0.00343
All Scales 0.00063 ± 0.00021 0.00343
Figure 3.1 The steady state mean velocity field within the 150 ml 
reactor. A centralized upward flow is visible with a descending 
return flow located at the edges of the vessel.
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Figure 3.2 The steady state mean vertical velocity field of the 
150 ml reactor. A centralized upward flow is visible with a 
descending return at the edges of the vessel.
Figure 3.3 Streamlines in the 150 ml steady state flow show the 
cross section of a vortex ring.
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Figure 3.4 Vortex location is highlighted to show areas included in 
vortex circulation within the 150 ml reactor at steady state.
Figure 3.5 The mean shear stress within the 150 ml reactor 
shows low shear homogeneity throughout the vessel.
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Mean Velocities of Scaled Vessels
1.25
1.00 T
150ml 125V 500V 1000V All Sizes
Figure 3.6 The mean velocity magnitude within the increasing sizes shows the mean to 
remain 0.5 mm/s ± 0.25 mm/s.
Velocity Magnitude Remains Steady at Larger Vessel
Sizes
Vessel Volume (ml)
125V Mean ........  500V Mean ........  1000V Mean
125 V Maximum 500V Maximum 1000V Maximum
Figure 3.7 The 125 V, 500V, and 1000V vessel sizes remain comparatively the same as 
the reactor is scaled up.
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Figure 3.8 The steady state mean velocity fields within the 125 V reactor for all tested 
volumes. A centralized upward flow is visible with a descending return flow located at 
the edges of the vessel. When the upper fluid boundary is higher at increased volumes, 
(A) 300 ml and (B) 250 ml, a centralized columnar flow is evident. At lower volumes, 
(C) 200 ml, (D) 150 ml, (E) 100 ml, the fluid boundaries near the core circulation of the 
vortex ring.
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Figure 3.9 The steady state mean velocity fields within the 500V reactor show a 
centralized upward flow with a descending return flow located at the edges of the 
vessel. (A) 1000 ml, (B) 900 ml, (C) 800 ml, (D) 700 ml.
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Figure 3.10 The steady state mean velocity fields within the smaller volumes of the 
500V reactor also show a centralized upward flow with a descending return flow 
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Figure 3.11 The steady state mean velocity fields within the 1000V reactor for all 
tested volumes. A centralized upward flow is visible with a descending return flow 
located at the edges of the vessel. Volumes tested include (A) 3000 ml, (B) 2500 
ml, (C) 2000 ml, (D) 1750 ml, (E) 1500 ml, (F) 1250 ml, (g ) 1000 ml, and (H) 750 
ml.
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Figure 3.12 The steady state streamlines within the 125V reactor for all tested volumes. 
Large rotations are seen with a centralized upward flow at all sizes. (A) 300 ml, (B) 250 
ml, (C) 200 ml, (D) 150 ml, (E) 100 ml.
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Figure 3.13 500V steady state streamlines. (A) 1000 ml, (B) 900 ml, (C) 
800 ml, (D) 700 ml, (E) 600 ml, (F) 500 ml, (G) 400 ml, (H) 300 ml.
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Figure 3.14 The steady state streamlines within the 1000V reactor for all tested 
volumes. Large rotations are seen with a centralized upward flow at all sizes. Volumes 
include: (A) 3000 ml, (B) 2500 ml, (C) 2000 ml, (D) 1750 ml, (E) 1500 ml, (F) 1250 
ml, and (G) 1000 .
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Figure 3.15 Instantaneous streamlines of the 900 ml volume in the 500V vessel sizes 
show rising vortex rings. Counter-rotational starting and stopping vortices are seen.
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Figure 3.16 The mean shear stress within the 125V reactor shows low shear 
homogeneity throughout the vessel. (A) 300 ml, (B) 250 ml, (C) 200 ml, (D) 150 
ml, (E) 100 ml.
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Figure 3.17 Low shear stress homogeneity in the 500V 
vessel. (A) 1000 ml, (B) 900 ml, (C) 800 ml, (D) 700 ml, 
(E) 600 ml, (F) 500 ml, (G) 400 ml, (H) 300 ml.
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Figure 3.18 Low shear homogeneity seen throughout the 1000V vessel size. Volumes 
tested include (A) 3000 ml, (B) 2500 ml, (C) 2000 ml, (D) 1750 ml, (E) 1500 ml, (F) 
1250 ml, (G) 1000 ml, and (h ) 750 ml.
52
Shear Stress Remains Steady at Larger Vessel 
Sizes
Vessel Volume (ml)
-------125V ------- 500V ------- 1000V
dvncsFigure 3.19 The shear stress within the vessel remains within a 0.002 range as the




The medical industry routinely experiences paradigm shifts as break-through 
technologies and innovation allow for new perspectives and revolutionize treatments. In 
recent decades, a major treatment paradigm has been the utilization of protein based 
therapeutics produced through large scale cell bioprocessing [1], [2]. Regenerative 
medicine and tissue engineering are poised to yet again shift the paradigm of medical 
treatment through the application of stem cell based therapeutics. For this to occur on a 
clinically relevant scale, the quantity and quality of stem cell production must match 
that presently seen in the protein bioprocessing industry. Current bioprocess mixing 
technologies were not designed to meet the delicate requirements of environmentally 
sensitive stem cells. Furthermore, recent designs which fulfill these requirements have 
faced significant challenges when scaled to larger sizes.
Our goal was to develop a novel mixing system that solves both conflicting 
suspension design challenges; namely creating a low shear homogenous mixing 
environment conducive to retention of an undamaged cell and unaltered phenotype, and 
maintaining that mixing environment as the design is scaled to larger volumes.
Novel Biomimetic Mixing Design 
The developed design incorporates both a legacy bioprocess technology and a 
biomimetic model. The Alternating Tangential Flow (ATF™) perfusion system 
marketed by Refine Technology utilizes an up and down motion to induce laminar flow 
across a filtration module connected to a bioreactor. Similarly, the proposed design uses 
this fundamental motion to create a mixing flow within a closed reactor vessel as seen 
in Figure 2.2.
Jellyfish propulsion has been studied by Dabiri et al. at the California Institute 
of Technology. Our design features geometric elements such as aspect ratio and 
structural elements such as the hinged flexible fins that contribute to the jellyfish 
rowing swim stroke [62]. More importantly, jellyfish create starting and stopping vortex 
rings on each stroke leading to an effective and efficient actuation. The fundamental 
schematic underlying vortex ring function is shown in Figure 4.1 [57], [59]. 
Instantaneous streamline analysis of the novel mixing design exhibits multiple counter- 
rotational starting and stopping vortices rising through the central column of the reactor 
flow, see Figure 3.15. As seen in jellyfish propulsion, this flow mechanism lends to 
highly efficient mixing by sucking in fluid along the reactor edges through the counter- 
rotational adjacent vortex superstructures.
Low Shear Mixing Maintained Through Scale-Up 
The results seen in the 150 ml vessel successfully met the design requirements 
of a low shear homogenous mixing environment. In line with the project goals, these 
flow characteristics were maintained as the design was scaled to larger sizes. Figure 4.2
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shows the maximum steady state velocity magnitudes are considerably lower than seen 
in impeller systems as the design is scaled [71]. The constancy of scale-up is more
dynes
drastically evident when compared to the lowest shear value, 0.3 , present in 
impeller stirred bioreactor designs as reported by Sucosky et al. [64], Figure 4.3.
Limitations
The method for quantification of the mechanical dynamics within the fluid flow, 
particle image velocimetry, is strongly dependent on the accuracy of particle placement 
in successive analysis frames. Due to the refraction in the curved surface of the vessel, 
secondary corrective image processing was required. Error inherent in this process will 
propagate in the quantifying computations. Additionally, the curvature of the vessel 
leads to areas along the vertical walls that are not visualized. Analysis of these areas is 
crucial as shear forces occur at the interfaces of boundaries, namely that of the fluid 
flow and the static wall. Finally, particle image velocimetry uses multiple interrogation 
windows in the cross correlation between images. In order to successfully capture 
displacement vectors, a larger interrogation window with an area of 80 pixels was used. 
Higher resolution and accuracy would be obtained with a smaller interrogation window. 
This may be accomplished through increased fluorescent bead density or through a 
higher capture frame rate. The frame rate used was limited by the low light conditions, 
whereas the high speed camera used was design for well-lit capture.
Scalability was limited to 3000 ml in the 1000V vessel due to fabrication cost 
constraints. Additionally, the curved bases of the 500V and 1000V sizes were not
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fabricated using cast acrylic as was the 125V due to cost constraints. This resulted in 
reduced visualization in the larger vessels.
Future Direction
Further characterization and development of the novel biomimetic mixing 
design is needed before this design can feasibly be utilized in a commercial setting. The 
design geometry and performance can be further optimized for the lowest shear and 
most homogenous mixing possible. The linear scaling factor of 1.5 times and the 
volume ranges for each vessel size can be verified through repetition of the experiments 
conducted herein and additional experiments could be conducted on considerably larger 
scales (10 L ^  100 L ^  1000 L).
The most important future study, however, highlights the interaction of the 
bioreactor performance on living stem cells in prolonged culture under full production 
conditions. This validation will require a sterile and sealed bioreactor system. Studies 
should be conducted to examine cell viability and expansion. Additionally, 
mesenchymal stem cells will be cultured and evaluated for phenotypic maintenance. 
The bioreactor would also need noninvasive sensing and real time feedback/control 
mechanisms to monitor and regulate the culture temperature, pH, CO2, and dissolved O2 
levels. The incorporation of perfusion, feeding, and automated harvesting has the 
potential to establish this system as an industrial benchmark and will have a large 
impact on the cell therapy industry. These elements, in combination with the optimized 
mixing profile have the potential to achieve high levels of cell expansion through 
predictable flow environments.
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In conclusion, we have used a requirements based design approach to 
successfully design and develop a novel proof of concept prototype that integrates the 
needs of delicate stem cell expansion, the legacy ATF™ system technology, and 
innovative biomimetic elements into a novel mixing system (Figure 4.4). The system 
has been shown to maintain low mean velocity and consequently low shear stresses. 
Furthermore, the mixing system has been successfully scaled across the 100 -  3000 ml 
range. This study provides the foundation for further optimization and development of 
the complete bioreactor system for the expansion of mesenchymal stem cells for tissue 
engineering and regenerative medicine.
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Figure 4.1 Starting and stopping vortices in the vortex wake created by the biomimetic 
diaphragm. Efficient mixing is facilitated by the induced flow between starting and 
stopping vortices. Figure adapted with permission [57].
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Scaled Velocity Magnitude is Lower than 
Impeller Mixed Systems
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Figure 4.2 The maximum steady state velocity magnitudes remain considerably lower 
than seen in impeller mixed systems (Sucosky) while scaled.
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Figure 4.3 The steady state shear stress remains orders of magnitude lower than seen in 












Figure 4.4 The design process consists of two primary phases, Design Input and Design 
Output. Requirements and Specifications were generated in Design Input which were 
then embodied in a testable prototype and verified through testing in Design Output.
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